ArticleAnnals of medicine2025
Prognostic analysis of steroid-induced osteonecrosis of the femoral head in children with immune kidney disease.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlucocorticoid (GC) is the first-line treatment for immune kidney diseases; long-term or excessive use of GC can lead to steroid-induced osteonecrosis of the femoral head (SONFH). We analysed the clinical prognosis and associated factors of SONFH in children with immune kidney disease treated with GC. MATERIALS AND
methodsWe conducted a retrospective analysis at our hospital between January 2012 and December 2022. Clinical data included sex, age, and body weight at the time of the first GC treatment, and GC dose associated with GC treatment. Hip joint function during the last follow-up was used as prognostic outcome. Participants were divided into poor (MDP hip score, <8 points) and medium-excellent groups (9-18 points), and nonparametric test and Spearman correlation analysis were performed.
resultsWe included 15 children with SONFH. The median age and weight at initial GC treatment were 12.67 (10.75, 14.83) years and 40.00 (37, 50) kg, respectively. The average follow-up time was 4.45 ± 2.54 years, and at last follow-up, 14 patients had bilateral SONFH Nonparametric tests revealed that age at initial GC treatment was older for children with poor hip joint scores (14.83 [12.5-16.4] years) than for those with medium-to-excellent scores (11.50 [10.5-13.8] years) (
conclusionsSONFH primarily manifests as bilateral onset, and the age at initial GC treatment and first-month GC dose were associated with hip joint prognosis of children with SONFH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.